Filed by Corgentech Inc. Pursuant to Rule 425
Under the Securities Act of 1933
And Deemed Filed Pursuant to Rule 14a-12
Under the Securities Exchange Act of 1934
Subject Company: AlgoRx Pharmaceuticals, Inc.
Commission File No. of Subject Company: 000-51146
*** *** ***
The following is an invitation for an analyst/investor luncheon sent to investors on October 14, 2005.
You are cordially invited to attend an analyst / investor luncheon next Friday with AlgoRx and Corgentech management for a review of clinical data from multiple trials of ALGRX 3268 and ALGRX 4975 and for a discussion of the marketing opportunities for these promising products.
WHEN: Friday, October 21st, 2005 - 11:30am - 1:30pm
11:30am—Registration begins |
12:00pm—Webcast program begins |
WHERE: Helmsley Park Lane Hotel
36 Central Park South, New York |
WHAT TO EXPECT:
— Clinical data review for ALGRX 3268 and ALGRX 4975 |
— Marketing opportunities for ALGRX 3268 and ALGRX 4975 |
— Review of proposed merger between AlgoRx and Corgentech |
— Q&A with management of AlgoRx and Corgentech |
— Plated lunch to be served during webcast presentation |
RSVP: Jennifer Williams
williams@corgentech.com OR 650-246-6963 |
Please RSVP by Tuesday, October 18th, at 6pm
We hope you will be able to join us, but in the event that you can not, you may access the live webcast or the webcast replay through the Investor Information page of our website,www.corgentech.com.